Seven biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
Stemline Therapeutics, Inc. (STML) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. For more information, get Portfolio Grader’s complete analysis of STML stock.
Pharmacyclics, Inc. (PCYC) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. For more information, get Portfolio Grader’s complete analysis of PCYC stock.
Acorda Therapeutics, Inc.’s (ACOR) ratings are looking better this week, moving up to a B from last week’s C. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.
Northwest Biotherapeutics, Inc. (NWBO) gets a higher grade this week, advancing from a C last week to a B. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. For more information, get Portfolio Grader’s complete analysis of NWBO stock.
BioMarin Pharmaceutical (BMRN) improves from a C to a B rating this week. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of BMRN stock.
Seattle Genetics, Inc. (SGEN) boosts its rating from a C to a B this week. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of SGEN stock.
This is a strong week for Amgen (AMGN). The company’s rating climbs to A from the previous week’s B. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. At present, the stock has a dividend yield of 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
